India’s Supreme Court dismissed Roche’s petition and allowed Natco Pharma to sell a lower‑cost generic version of Evrysdi (risdiplam) in India, a decision described in coverage as weighing public interest in access against manufacturer profits. The generic price cited was approximately $179 per bottle versus Roche’s list price of $6,982, a gap that could materially affect patient access and market dynamics for spinal muscular atrophy (SMA) treatments in India. The ruling could set precedent for future compulsory‑access disputes in high‑cost rare‑disease drugs and increase pressure on multinational pharma pricing strategies in low‑ and middle‑income markets. Roche will need to reassess global access programs and legal options while stakeholders evaluate the impact on availability and patient assistance.